Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancerYanjing Li, Jiaoti Huang, Yinglu Zhou et al.|Science Translational Medicine|2019Cited by 138
Rewiring of the N-Glycome with prostate cancer progression and therapy resistanceWilliam Butler, Jiaoti Huang, Colin T. McDowell et al.|npj Precision Oncology|2023Cited by 22
Oncofetal protein glypican‐3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancerWilliam Butler, Jiaoti Huang, Lingfan Xu et al.|The Journal of Pathology|2023Cited by 19